Key Highlights
Abbott Laboratories reported its Q1 2026 earnings on April 16, exceeding Wall Street's revenue expectations, with a recent acquisition in the cancer diagnostics business providing additional momentum for the company.
Abbott Laboratories Q1 2026 Earnings
- Adjusted earnings per share (EPS) of $1.15 (expected $1.15)
- Net sales reached $11.16 billion (expected $11.01 billion)
- Expected adjusted EPS for Q2 between $1.25 and $1.31 (expected $1.31)
- Expected organic sales growth for the year of 6.5% to 7.5% (expected growth of 6.87%)
During this three-month period, Abbott reported an adjusted EPS of $1.15, in line with one analyst's forecast and one cent higher than another consensus estimate of $1.14, with specific figures varying by data provider.
Quarterly revenue reached $11.16 billion, surpassing Wall Street's expectation of $11 billion.
The acquisition of Exact Sciences has impacted the financial performance this quarter. Abbott completed the agreement to acquire the cancer diagnostics company at a price of $105 per share last November, with a total transaction value of approximately $23 billion, finalized in March 2026.
This deal is one of the most significant acquisitions in Abbott's history, marking the company's active expansion in the field of tumor diagnostics. The performance of the newly integrated unit contributed significantly to the revenue exceeding expectations in Q1.
Medical Device Division Maintains Growth Momentum
This healthcare giant has relied on its device business as a core growth engine for multiple quarters, a trend that continued in the first three months of 2026.
Outlook Slightly Below Expectations
For the entire fiscal year, Abbott expects earnings per share to be between $5.38 and $5.58, with Wall Street consensus at $5.47, falling right within this forecast range.
Over the past 90 days, Abbott has not experienced any upward revisions to its EPS forecast, but rather has seen 18 downward adjustments, indicating a deterioration compared to the previous quarter's “strong performance” financial health assessment—InvestingPro currently rates Abbott's financial health as “good performance.”
Although the guidance did not fully meet market expectations, the revenue exceeding performance still brings a degree of confidence. Abbott's top-line execution in Q1 is a stronger component of this quarter's report.
The consensus for full-year EPS is $5.47, still within Abbott's expected range of $5.38 to $5.58, providing flexibility for the company's subsequent performance in the fiscal year to meet or exceed this benchmark.